Raj Chovatiya, MD, PhD

Peter A. Lio, MD, describes the challenges pediatric patients face with oral therapies for atopic dermatitis, focusing on ease of administration and patient adherence.

Raj Chovatiya, MD, PhD; Brittany G. Craiglow, MD; and Peter A. Lio, MD, highlight challenges physicians face with the available atopic dermatitis treatments for pediatric patients.

Dr Peter A. Lio shares his advice for curating an atopic dermatitis treatment plan and explains the difference between rescue and maintenance treatments.

Dr Brittany G. Craiglow provides an overview of her approach to use of nonpharmacological agents in the treatment of her pediatric patients with atopic dermatitis.

Raj Chovatiya, MD, PhD, and Brittany G. Craiglow, MD, share their opinions on how they assess and what they define as treatment success in their pediatric patients suffering from atopic dermatitis.

Experts in dermatology review the treatment landscape for pediatric patients with atopic dermatitis.

Dr Brittany G. Craiglow discusses the impact of disease burden on both the patient and their caregivers, with a focus on how this burden evolves as a patient ages.

Brittany G. Craiglow, MD, and Peter A. Lio, MD, provide insight into the challenges inherent to an atopic dermatitis diagnosis, focusing on the role of diet and a patient’s clinical presentation.

Experts in dermatology comment on the heterogeneity of atopic dermatitis and how this affects clinical practice decisions, patient quality of life, and disease burden.

Raj Chovatiya, MD, PhD; Brittany G. Craiglow, MD; and Peter A. Lio, MD, provide insight into pediatric atopic dermatitis, focusing their discussion on the pathophysiology, prevalence, and disease symptomology.

Elizabeth A. Swanson, MD, and Raj. J. Chovatiya, MD, PhD, examine challenges in managing atopic dermatitis and explore the evolving treatment landscape.

Korey Capozza, MPH; Elizabeth A. Swanson, MD; and Taylor Capps share pearls for patients and their families managing atopic dermatitis.

Korey Capozza, MPH, highlights the importance of patient advocacy in the atopic dermatitis journey.

Raj J. Chovatiya, MD, PhD; Elizabeth A. Swanson, MD; Tina Capps; and Taylor Capps assess barriers in finding and obtaining atopic dermatitis treatments.

Elizabeth A. Swanson, MD, discusses the safety and efficacy of dupilumab in treating moderate to severe atopic dermatitis, and Taylor Capps shares her journey with dupilumab from insurance approvals through receiving treatment.

Raj J. Chovatiya, MD, PhD, reviews goals of therapy for patients with atopic dermatitis and comments on the use of various topical therapies and systemic agents for disease management.

Korey Capozza, MPH, examines the role of multidisciplinary care for patients with atopic dermatitis, and Taylor Capps shares the impact of atopic dermatitis on mental health.

Elizabeth A. Swanson, MD, provide insight on identifying the appropriate patients for various therapeutic regimens in atopic dermatitis.

Raj J. Chovatiya, MD, PhD, discusses the level of awareness of atopic dermatitis within the medical community and approaching the management of disease.

Raj J. Chovatiya, MD, PhD; Alexandra K. Golant, MD; Eric Simpson, MD, MCR; and Linda Stein Gold, MD, share clinical pearls and discuss the future treatment landscape for atopic dermatitis.

Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, discuss challenges adolescent and adult patients face with current oral and topical therapies and optimizing disease management.

Experts in the management of atopic dermatitis assess the use of JAK inhibitors in clinical practice and considerations for treatment selection for patients with atopic dermatitis.

Elizabeth A. Swanson, MD, describes the burden of atopic dermatitis on the pediatric and adult patient populations.

Raj J. Chovatiya, MD, PhD, reviews the clinical manifestations and underdiagnoses of atopic dermatitis.

Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, share their approach to prescribing decisions for oral and topical JAK inhibitors for patients with atopic dermatitis.

Drs Alexandra K. Golant, Raj J. Chovatiya, Linda Stein Gold, and Eric Simpson comment on clinical implications of boxed warnings for the utilization of JAK inhibitors when treating atopic dermatitis.

Korey Capozza, MPH, offers insight into changing public perception of atopic dermatitis and bridging unmet needs in the field.

Taylor and Tina Capps assess the burden of atopic dermatitis on Taylor’s life and the impact on her family.

Eric Simpson, MD, MCR, leads a discussion on current FDA approved topical and systemic JAK inhibitors for the management of atopic dermatitis.

Alexandra K. Golant, MD, highlights factors to consider when recommending the use of JAK inhibitors to manage atopic dermatitis for various patient populations.